Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals.

ABSTRACT: In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because their use may lead to excellent cure rates with fewer side effects. In Latin America, the high prevalence of HCV genotype 1 infection and the significant association of Native American ancestry with risk predictive single-nucleotide polymorphisms (SNPs) in IFNL4 and ITPA genes highlight the need to implement new treatment regimens in these populations. However, the universal accessibility to DAAs is still not a reality in the region as their high cost is one of the major, although not the only, limiting factors for their broad im

SUBMITTER: Trinks J 

PROVIDER: S-EPMC5378445 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature